



Vaccine Adjuvants Research

Guest Editor:

Prof. Dr. Olga Borges

Center for Neurosciences and Cell Biology (CNC), Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal

Deadline for manuscript submissions:

closed (31 July 2023)

Message from the Guest Editor

The appearance of the SARS-CoV-2 virus in 2020 brings, again, to public discussion, the importance of being prepared for the development of vaccines in a short period of time. Reverse vaccinology and proteomic approaches have allowed rapid identification of the antigenic structures and, thus, the design of a successful vaccine. A huge diversity of vaccines is being tested, based on RNA, DNA, recombinant proteins, inactivated and attenuated virus, and viral vectors. Appropriate adjuvants for these vaccines are not approved and need to be developed not only for injectable vaccines but, also, to obtain more stable, needle-free, oral, and intranasal vaccines. These last modalities would help to not only increase the vaccine coverage but also more rapidly, and to decrease the infections associated with bad clinical practice during the administration of injectables, especially in developing countries. The objective of this Special Issue of *Vaccines* is to cover the most recent developments in vaccine adjuvants and formulations.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition
and Behavior, University College
Roosevelt, 4331 CB Middelburg,
The Netherlands

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

Journal Rank: JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com
[X@Vaccines_MDPI](https://twitter.com/Vaccines_MDPI)